BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16151677)

  • 1. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
    Choi JY; Shin A; Park SK; Chung HW; Cho SI; Shin CS; Kim H; Lee KM; Lee KH; Kang C; Cho DY; Kang D
    Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women.
    Kim H; Chun S; Ku SY; Suh CS; Choi YM; Kim JG
    Menopause; 2009; 16(5):1014-20. PubMed ID: 19369902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men.
    Yamada Y; Ando F; Niino N; Shimokata H
    Mol Genet Metab; 2003 Nov; 80(3):344-9. PubMed ID: 14680982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women].
    Cheng Q; Zhu HM; Miao YX; Zhu XY; Chen XP; Zhang XM
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):274-7. PubMed ID: 15059506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women.
    Arko B; Prezelj J; Kocijancic A; Komel R; Marc J
    Maturitas; 2005 Jul; 51(3):270-9. PubMed ID: 15978970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SULT1E1 genetic polymorphisms modified the association between phytoestrogen consumption and bone mineral density in healthy Korean women.
    Lee SA; Choi JY; Shin CS; Hong YC; Chung H; Kang D
    Calcif Tissue Int; 2006 Sep; 79(3):152-9. PubMed ID: 16969590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
    Rhee EJ; Oh KW; Lee WY; Kim SY; Oh ES; Baek KH; Kang MI; Kim SW
    Am J Obstet Gynecol; 2005 Apr; 192(4):1087-93. PubMed ID: 15846185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta.
    Vidal C; Brincat M; Xuereb Anastasi A
    Maturitas; 2006 Mar; 53(4):386-95. PubMed ID: 16343827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-nucleotide polymorphisms and haplotypes of bone morphogenetic protein genes and peripheral bone mineral density in young Korean men and women.
    Choi JY; Shin CS; Hong YC; Kang D
    Calcif Tissue Int; 2006 Apr; 78(4):203-11. PubMed ID: 16604289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.
    Mencej S; Prezelj J; Kocijancic A; Ostanek B; Marc J
    Maturitas; 2006 Oct; 55(3):219-26. PubMed ID: 16730419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
    Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density.
    Mencej-Bedrac S; Prezelj J; Kocjan T; Teskac K; Ostanek B; Smelcer M; Marc J
    J Mol Endocrinol; 2009 Mar; 42(3):239-47. PubMed ID: 19131500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men.
    Hsu YH; Niu T; Terwedow HA; Xu X; Feng Y; Li Z; Brain JD; Rosen CJ; Laird N; Xu X
    Hum Genet; 2006 Jan; 118(5):568-77. PubMed ID: 16249885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.